Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.44 |
| ▸ | SMCHD1 | A6NHR9 | 1/20 | 0.41 |
| ▸ | MYO1G | B0I1T2 | 1/20 | 0.41 |
| ▸ | AIP | O00170 | 1/20 | 0.41 |
| ▸ | AP3B1 | O00203 | 1/20 | 0.41 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | SAP18 | O00422 | 1/20 | 0.41 |
| ▸ | KPNA3 | O00505 | 1/20 | 0.41 |
| ▸ | PPP6C | O00743 | 1/20 | 0.41 |
| ▸ | TCERG1 | O14776 | 1/20 | 0.41 |
| ▸ | UBE2L6 | O14933 | 1/20 | 0.41 |
| ▸ | PPP1R12A | O14974 | 1/20 | 0.41 |
| ▸ | U2SURP | O15042 | 1/20 | 0.41 |
| ▸ | SETD1A | O15047 | 1/20 | 0.41 |
| ▸ | ARPC1B | O15143 | 1/20 | 0.41 |
| ▸ | POLR1C | O15160 | 1/20 | 0.41 |
| ▸ | OGT | O15294 | 1/20 | 0.41 |
| ▸ | PPM1G | O15355 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607295 | 0.90 | BRD4 (0.44) | BRD4SMCHD1MYO1GAIPAP3B1 | |
| SCHEMBL605629 | 0.88 | BRD4 (0.42) | BRD4SMCHD1MYO1GAIPAP3B1 | |
| SCHEMBL609055 | 0.87 | BRD4 (0.45) | BRD4SMCHD1MYO1GAIPAP3B1 | |
| SCHEMBL14707979 | 0.86 | TP53 (0.51) | BRD4LMNABDKRB2 | |
| SCHEMBL608170 | 0.86 | BRD4 (0.45) | BRD4SMCHD1MYO1GAIPAP3B1 | |
| SCHEMBL606257 | 0.85 | BRD4 (0.43) | BRD4SMCHD1MYO1GAIPAP3B1 | |
| SCHEMBL8985784 | 0.85 | OPRK1 (0.51) | BRD4LMNAKCNH2HDAC3HDAC6 | |
| SCHEMBL10193350 | 0.85 | BRD4 (0.48) | BRD4SMCHD1MYO1GAIPAP3B1 | |
| SCHEMBL607146 | 0.84 | BDKRB2 (0.43) | BRD4SMCHD1MYO1GAIPAP3B1 | |
| SCHEMBL12172317 | 0.84 | BRD4 (0.41) | BRD4SMCHD1MYO1GAIPAP3B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217576-B1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | UNIV MICHIGAN (US) | 2016-05-11 | — | — | EP | disclosed |
| US-8759340-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-8461153-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-11 | — | — | US | disclosed |
| US-8188072-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120040971-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2217576-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | The Regents of the University of Michigan (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061916-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040971-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | BRD4 109/4885SMCHD1 4659/4885MYO1G 4694/4885 |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | BRD4 109/4885SMCHD1 4659/4885MYO1G 4694/4885 |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | BRD4 109/4885SMCHD1 4659/4885MYO1G 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.